Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

The BCL-2 inhibitor venetoclax improves survival for adult patients with acute myeloid leukemia (AML) in combination with lower-intensity therapies, but its benefit in pediatric patients with AML remains unclear. We retrospectively reviewed two Texas Medical Center institutions’ experience with vene...

Full description

Bibliographic Details
Main Authors: Adriana Trabal, Amber Gibson, Jiasen He, David McCall, Michael Roth, Cesar Nuñez, Miriam Garcia, Meredith Buzbee, Laurie Toepfer, Aram Bidikian, Naval Daver, Tapan Kadia, Nicholas J. Short, Ghayas C. Issa, Farhad Ravandi, Courtney D. DiNardo, Guillermo Montalban Bravo, Sofia Garces, Andrea Marcogliese, Hana Paek, Zoann Dreyer, Julienne Brackett, Michele Redell, Joanna Yi, Guillermo Garcia-Manero, Marina Konopleva, Alexandra Stevens, Branko Cuglievan
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
acute myeloid leukemia
pediatric
children
venetoclax
Bcl-2 inhibitor
Online Access:https://www.mdpi.com/2072-6694/15/7/1983

Internet

https://www.mdpi.com/2072-6694/15/7/1983

Similar Items